Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CATALYST PHARMACEUTICALS, INC. entered into Underwriting Agreement with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement valued at 10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a public offering pr (effective 2024-01-04).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement
- Value
- 10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a public offering pr
- Effective
- 2024-01-04
Exact text from the filing
On January 4, 2024, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement (collectively, the “ Underwriters ”), relating to the public offering, issuance and sale (the “ Offering ”) by the Company of 10,000,000 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a public offering price of $15.00 per share, less underwriting discounts
View on SEC.gov